Muscular Dystrophy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have a mutation in the LMNA gene that has led to a diagnosis of a condition called "laminopathy" that affects the muscles
- You have symptoms of the disease, such as muscle weakness or tendon tightening, with or without breathing or heart problems
- You are either the first person in your family diagnosed with this condition, or you are a family member related to that person
- You are able to safely have a small sample of muscle or skin taken (a biopsy) — meaning you do not have allergies to latex, antiseptics, local anesthetics, or adhesive dressings, you are not currently taking blood-thinning medications, and you do not have a bleeding disorder
- You (if an adult) or both of your child's legal guardians (if the patient is a minor) are willing and able to sign a consent form agreeing to take part
- You are covered by the French social security system, French Universal Medical Coverage (CMU), or an equivalent French scheme
Who may not be able to join:
- Women who are currently pregnant or breastfeeding
- Adults who are under a legal protection order, such as court protection, curatorship, or guardianship
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +33142165724
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Skeletal muscle severity outcome; Cardiac muscle severity outcome; Protective structural variant outcome; Protective differential gene expression outcome; Protective 3D chromatin conformation outcome; Aggravating structural variant outcome; Aggravating differential gene expression outcome; Aggravating 3D chromatin conformation outcome outcome
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.